Larry Anderson

Professor

University of Texas Southwestern Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Larry Anderson is a Professor at the University of Texas Southwestern Medical Center in the United States. His research primarily focuses on multiple myeloma, exploring various aspects such as minimal residual disease, treatment outcomes with novel therapies, and the impact of healthcare policies on cancer patient populations. Recent articles by Dr. Anderson highlight significant interventions and findings related to multiple myeloma treatment and population health, contributing to advancements in the field.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (17)

Mounzer Agha

Associate Professor

University of Pittsburgh

UNITED STATES

Larry Anderson

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.

Toxicity of CAR T-Cell Therapy for Multiple Myeloma.

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Unusual paraneoplastic neurological presentation associated with multiple myeloma

Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States

Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

More key players in the game for myeloma prognosis and therapy

Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis

Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma

Collaborators (17)

Mounzer Agha

Mehdi Hamadani

Brandi N. Reeves

Shahzad Raza

Naveen Premnath

Abdullah Khan

Noopur Raje

Irene Ghobrial

Robert Orlowski

Benjamin Derman

Sagar Lonial

Ajay K. Nooka

Aurore Perrot

William Drobyski

Bruno David Lourenço Paiva

Navid Sadeghi

Anthony Zamora

Make your next move.